{"name":"Xilio Therapeutics","slug":"xilio","ticker":"XLO","exchange":"NASDAQ","domain":"xiliotx.com","description":"Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.","hq":"Waltham, MA","founded":0,"employees":"76","ceo":"René Bhatt","sector":"Immuno-Oncology","stockPrice":8.49,"stockChange":-0.01,"stockChangePercent":-0.12,"marketCap":"$49M","metrics":{"revenue":43766000,"revenueGrowth":693.9,"grossMargin":100,"rdSpend":56039000,"netIncome":-35036000,"cash":137531008,"dividendYield":0,"peRatio":-14.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Xilio Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Xilio Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting progress in its clinical pipeline and operational efficiency.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Xilio Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany to Develop and Commercialize XLO1","summary":"Xilio Therapeutics announced a collaboration with Merck KGaA, Darmstadt, Germany to develop and commercialize XLO1, a first-in-class, orally administered, small molecule inhibitor of the tumor microenvironment.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxORnNFT1N3dTFMdVhHSVZmUDlsVWZPNHJfckJ3Z2ZSakgxY1c2WTA0UmpOSFJtWW9qam1SamF5bl90RHFTQ3J0QW9qV2Z4SXU0VW5PeWhIa21KVm1Fem1lVDBmZTA0Wjc2N1RKZmViQno0b1QwYnFQMHZQLUpBZmQ4bWlxajhyLU1pc1dfYWU1WUVTOUw5V2FERGNFY1lDR1Q0UEg4bmJxZERZUWM4?oc=5","date":"2026-03-23","type":"deal","source":"Stock Titan","summary":"Xilio Therapeutics (XLO) outlines masked immuno-oncology pipeline and big pharma deals - Stock Titan","headline":"Xilio Therapeutics (XLO) outlines masked immuno-oncology pipeline and big pharma deals","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFByMXVXQ29USHlfckRvd1ZDUGNkcENLaGF0N09sTDNLN3V6UVNWcGpjdlFfNFIzUXo4cHBhY2lCZE1kSFVPQmJGOXdmQV9wNnExOEpaN016RWlvUWxKcWlRQUhsV0RHT19BWHRoUA?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Xilio Therapeutics, Inc. (XLO) - Stock Titan","headline":"If You Invested $1,000 in Xilio Therapeutics, Inc. (XLO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNTkY0dXU5MkVnM2lFWWV3ZTNYMXJ1ejVibmxGaXo5d0lEX2lZVkpIUHgtdzRlTS1vYmltVm5iazRxWEFsVWw4b0liODNuaS1ubUNraE5uOS1MWjZXZTI0LXE2dnJaOXc3OUEzQXYzSW9yU1I2cE1kVS04dXUxZS1hdV9RQWVQbHpXZFp2VUJLd0hzWTJva2NCZWd1Y25JVFREdkR0V2dFX3E?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Cancer biotech Xilio enacts 1-for-14 reverse split to regain Nasdaq compliance - Stock Titan","headline":"Cancer biotech Xilio enacts 1-for-14 reverse split to regain Nasdaq compliance","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQTHVLUXNYNDJCa0xjbTJjUVU1djg4ZVJoakZvc1RrcGtEejZFdHRRZHQyS0ZHNkhnaTVzcFFrTTYtejZrR2FnV2w3UG5MUVNZTXowc2NySGFjamlpRWtVdEtjRUVfVU44SWJQQ1JPX3dLd1NlZ2JlM29FVUd0a0FGWVFmVzV6SGc3S2V4YVhmZERJTl9xaEhVQXFucUdyQTVPSndRN1VRWUlIRjBNU0RB?oc=5","date":"2026-02-24","type":"pipeline","source":"Stock Titan","summary":"Xilio Therapeutics (NASDAQ: XLO) gains stockholder OK for reverse stock split range - Stock Titan","headline":"Xilio Therapeutics (NASDAQ: XLO) gains stockholder OK for reverse stock split range","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNUk03Tnc2Yk9HZVg4VWdMZk9HMWJCWWt4cHRTbGFnQzhkcld0b2JjMkwzMEx4OHZRSkNqaTh6UU1VYXJJUkRKN3Q0eE1UY1hZUDJoeElBZTZ5VDJmcEFqUHdJWUxuMWZXeWNhRWhGS2c3bUVzSEUySUh4aXRNckxTWDQ0Zjh6dTAwRzRObG9UVUNIR3Vuc2hNM3owcXNNdUNYQkVHQmw5TGFDcHh5eHlUYzVSR3Q?oc=5","date":"2026-01-08","type":"pipeline","source":"Stock Titan","summary":"Biotech Xilio brings in $35.8M to advance masked cancer therapies - Stock Titan","headline":"Biotech Xilio brings in $35.8M to advance masked cancer therapies","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5hUzhWVl8xWVVPTjNuWUZxR2QyQVpOdk1pRmV3aVh6ZUJZekxXcmxTMnZYRXowQklUZmdJU1Q0LW5sSFpPV1FYcXNlbjRRdkx4c1U0VndmcS1jZ1RHX3YxNDlFTkFWelk?oc=5","date":"2025-07-10","type":"regulatory","source":"MarketBeat","summary":"Xilio Therapeutics (XLO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $XLO - MarketBeat","headline":"Xilio Therapeutics (XLO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $XLO","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9zT3FZSVdTQS1iTGNXVUdHRzk2M1lxTFJHWjlTN0hEanNJUHN6LVpfcU9zMldyc1p5WjJlYnU5Qkl4NWc2aEdmM29IZEJsOTZsUG1MMXZqcGFqVjhJdjVPM28yX00?oc=5","date":"2024-05-11","type":"pipeline","source":"MarketBeat","summary":"Xilio Therapeutics (XLO) Stock Forecast and Price Target 2026 $XLO - MarketBeat","headline":"Xilio Therapeutics (XLO) Stock Forecast and Price Target 2026 $XLO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNcEZjd21GOXdQLWxXbXlpblFNUTF5eS1uVGZtaDFGQldOYTRxOEFNYUl0aGlOWDBHRmdoRmo0S282Mmx6RFdzQmh5LWk3YTIxVjdUdGJNckZPMWtpSEExQ1daaHpkQ0dXd3FoX1Y0UHBEVEV3YXdvTTZUaXNyN2ZUU3dsVVRGdUM3eGEw?oc=5","date":"2024-03-28","type":"pipeline","source":"InvestorPlace","summary":"Why Is Xilio Therapeutics (XLO) Stock up 168% Today? - InvestorPlace","headline":"Why Is Xilio Therapeutics (XLO) Stock up 168% Today?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Eli Lilly and Company"],"therapeuticFocus":["Immuno-Oncology"],"financials":{"source":"sec_edgar","revenue":43766000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":43766000,"period":"2025-12-31"},{"value":6344000,"period":"2024-12-31"},{"value":6344000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":56039000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-35036000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":154685000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.49,"previousClose":8.5,"fiftyTwoWeekHigh":16.52,"fiftyTwoWeekLow":6.47,"fiftyTwoWeekRange":"6.468 - 16.52","fiftyDayAverage":7.91,"twoHundredDayAverage":9.57,"beta":-0.12,"enterpriseValue":-81425656,"forwardPE":-14.6,"priceToBook":1.09,"priceToSales":1.12,"enterpriseToRevenue":-1.86,"enterpriseToEbitda":2.01,"pegRatio":0,"ebitda":-40441000,"ebitdaMargin":-92.4,"freeCashflow":8027250,"operatingCashflow":-4992000,"totalDebt":6954000,"debtToEquity":19.7,"currentRatio":2.58,"returnOnAssets":-23.2,"returnOnEquity":-132.5,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":1,"targetMeanPrice":20,"targetHighPrice":20,"targetLowPrice":20,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":29.5,"institutionHeldPercent":35.4,"sharesOutstanding":5782511,"floatShares":3451407,"sharesShort":159408,"shortRatio":5.22,"shortPercentOfFloat":3,"epsTrailing":-58.66,"epsForward":-0.58,"revenuePerShare":9.66,"bookValue":7.79,"officers":[{"age":50,"name":"Dr. Rene  Russo BCPS, Pharm.D.","title":"President, CEO & Director"},{"age":43,"name":"Mr. Christopher  Frankenfield","title":"CFO & COO"},{"age":49,"name":"Dr. Katarina  Luptakova M.D.","title":"Chief Medical Officer"},{"age":55,"name":"Mr. Kevin M. Brennan","title":"Senior Vice President of Finance & Accounting"},{"age":null,"name":"Dr. Uli  Bialucha Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Nathan  McBride","title":"Chief Information Officer"},{"age":null,"name":"Ms. Caroline  Hensley","title":"Chief Legal Officer"},{"age":null,"name":"Dr. Scott  Coleman Ph.D.","title":"Chief Development Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://xiliotx.com","phone":"857 524 2466"}}